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23	SELECTED B-VITAMINS AND THEIR POSSIBLE LINK TO THE AETIOLOGY OF AGE-RELATED






26	The possible roles of selected B-vitamins in the development and progression of sarcopenia are

27	reviewed. Age-related declines in muscle mass and function are associated with huge and increasing

28	costs to healthcare providers. Falls and loss of mobility and independence due to declining muscle

29	mass/function are associated with poor clinical outcomes and their prevention and management are

30	attractive research targets. Nutritional status appears a key modifiable and affordable intervention .

31	There is emerging evidence of sarcopenia being the result not only of diminished anabolic activity

32	but also of declining neurological integrity in older age, which is emerging as an important aspect

33	of the development of age-related decline in muscle mass/function. In this connection, several B-

34	vitamins can be viewed as not only co -factors in muscle synthetic processes, but also as

35	neurotrophic agents with involvements in both bioenergetic and trophic pathways. The B-vitamins

36	thus selected are examined with respect to their relevance to multiple aspects of neuromuscular

37	function and evidence is considered that requirements, intakes or absorption may be altered in the

38	elderly. In addition, the evidence base for recommended intakes (UK RDAs) is examined with

39	particular reference to original data sets and their relevance to older individuals. It is possible that

40	inconsistencies in the literature with respect to the nutritional management of sarcopenia may, in

41	part at least, be the result of compromised micronutrient status in some study participants. It is

42	suggested that in order, for example, for intervention with amino acids to be successful, underlying






45	The term ‘sarcopenia’ was coined in 1989 to describe an age-associated process characterised by a

46	decline in human skeletal muscle mass(1). This definition has been extended to include the

47	associated loss of muscle function (strength and power), which represents the primary qualitative

48	concern due to its link with frailty(2–4). Sarcopenia is also described by a measure of total lean mass
49	
50	≥2 standard deviations below that of a comparable young adult, distinguished by a reduction in

51	muscle fibre number and cross-sectional area(2). This loss is often described as irreversible and

52	associated with a significant functional deficit, leading to a loss of physical independence(4,5).

53	Sarcopenia is associated with an increased risk of falls and related fractures (6,7).

54	The population in the UK is ageing; the elderly sector of the population is increasing independent of













55	together, 18-21% of the European population were found to be aged 65 or over and this range is

56	expected to rise to 19-31% by 2035, which translates to >25% of all Europeans being aged 65 or

57	over by that date(8). There are at present few initiatives or therapeutic protocols in place to manage

58	sarcopenia at the level of the general population. Research is emerging that indicates that the lean

59	tissue decrements and increased frailty associated with ageing may be relatively manipulable

60	phenomena, with nutrition as a key modifiable variable.

61	Nutritional interventions, for example with essential amino acids, have produced rather variable

62	results, with some interventions appearing effective and others of limited value (9–11). In such

63	research, elderly sarcopaenic subjects frequently present with multiple, potentially confounding

64	factors. In this connection, the present discussion will examine the potential role of selected B

65	vitamins in normal and pathophysiological modes of neuromuscular function. Several key themes

66	will be explored, notably issues associated with the adequacy of the knowledge base regarding older

67	adults’ requirements and intakes for B -vitamins, the similarities between certain deficiency and

68	frailty states associated with older age and finally the potential for sub-optimal micronutrient status

69	to mimic/mask features of sarcopenia.


70	NUTRITIONAL CHALLENGES IN LATER LIFE

71	Age-related features underlying compromise of intake or processing of nutrients are manifold and

72	range from the psychosocial through to the physiologic. In later life, issues of reduced income,

73	mobility and socialization may conflate to produce a reduction in calorie and nutrient intake per se

74	(12,13). Problems with dental health may impair intake regardless of food availability(14,15), while

75	changes in taste perception can also occur with ageing(16). In addition, the elderly may experience

76	difficulty interpreting labelling information(17), which, combined with economic limitations, may

77	present the older adult with less appetizing meal options. Many elderly regularly take medications

78	and these can alter the uptake, metabolism and/or excretion of key nutrients(18,19). Disease states

79	such as cancer, diabetes and gastrointestinal inflammatory disorders also impact directly on

80	nutritional status. There is considerable evidence that the elderly are at significant risk of two or

81	more micronutrient deficiencies(20–23) and it has been established that there is a clear association

82	between multiple micronutrient deficiencies and frailty(24,25). The elderly therefore represent an ‘at

83	risk’ group for malnutrition and deficiency states that may have causal or aggravating connections

84	to sarcopenia. With respect to the very elderly (85+) a study in the UK found lower than estimated

85	average requirements for energy and highlighted the lack of dietary intake (DI) data and the

86	uncertainties about DRVs for very old adults (26).














88	The rationale for selecting B-vitamins is as follows. Firstly, B-vitamins are involved in multiple

89	aspects of energy and protein metabolism, and also in multiple aspects of neural integrity and

90	function. Secondly, deficiencies of B-vitamins may manifest in obvious neuromuscular problems

91	(e.g. beri beri) and/or neurological symptoms (e.g. pellagra, peripheral neuropathies). Some of these

92	signs and symptoms could mask or exaggerate key features of a number of age-related syndromes

93	such as sarcopenia. Finally, in older adults, possible sub-optimal DIs (DI) of B-vitamins, issues of

94	impaired absorption and age-related anorexia potentially combine to produce a sector of the

95	population for which B-vitamin deficency is a reality. The long-term effects of sub-clinical

96	deficiencies remain poorly understood.

97	The aim of the present text therefore is to review known functions of selected B-vitamins in

98	connection with sarcopenia and to assess the likelihood of an interactive or additive effect of sub-

99	optimal B-vitamin status in the initiation, progression or extent of age-related decrements in muscle

100	mass and function. The B-vitamins that will be examined were selected on the basis of their known

101	roles in relevant physiological and metabolic processes and their potential for sub-optimal intake or

102	status in older adults.

103	With respect to determination of sufficiency or otherwise, issues of intake are considered alongside

104	biochemical indices where available, and contextualized through the lens of UK recommended

105	daily allowances (RDAs), which are the values that form the basis of advice and evaluation by most

106	of the UK-based science, health and public health organizations. Differences exist between the UK

107	RDAs and the European Food Safety Authority (EFSA) recommended daily intakes of B-vitamins

108	for the elderly, with EFSA values being higher in almost all cases. Differences also exist between

109	the values cited by EFSA and several European national guidelines, including those set by the

110	partner institutions of the German Nutrition Society (DGE), the Austrian Nutrition Society (AGE)

111	and the Swiss Nutrition Society (SGE). The present review therefore explores the rationale for the

112	current UK-recommended daily allowance(s) (RDAs) in particular.

113	The UK National Diet and Nutrition Survey (NDNS)(27), with respect to the elderly, presents

114	varying degrees of detail in terms of B-vitamin status, which is in some cases described by intake,

115	in other cases by plasma levels and in others by functional assays. While the latest data appear to

116	suggest a generally positive picture in terms of B-vitamin sufficiency for those living in the UK,

117	there are some important caveats. Firstly, while the NDNS provides important, up-to-date insight

118	into the nutritional status of the UK population, its findings are given meaning by national dietary

119	guidelines, which are often at considerable variance with estimated requirements for nearby,

120	comparable, modern industrial societies. Secondly, whilst the NDNS groups ‘the elderly’ within the

121	single age bracket of ≥65+, in many instances the authors acknowledge age-related declines in the













123	adults would appear to lose applicability with advancing age. In this connection, the latest survey

124	(2014/15) does not include samples from non-community dwelling (i.e. institutionalized) elderly

125	populations; the data presented for this survey is only for free-living individuals. This may in part

126	explain the discrepancies that exist between the latest results and the results of the previous study

127	(which indicated a greater prevalence of deficiency), since the latter included individuals living in

128	institutions as well as the free-living. As there is an increasing number of elderly people in care, and

129	since the non-community dwelling elderly represent a group at high risk of malnutrition, this may

130	well constitute an important oversight; one that may distort the perceived landscape of nutritional

131	health in the UK elderly population.

132	More generally, assessment of nutritional status in the elderly is for the most part based on

133	nutritional intake data e.g. from food frequency questionnaires (ffq), food diaries and food

134	purchasing data. Whilst such methods have utility in assessing patterns of consumption and

135	estimating energy intake, their application in determining micronutrient status in the elderly is

136	limited as follows. In general terms, these methods are not reflective of intra-population

137	requirements or rates of utilization, do not account for the significant changes in micronutrient

138	availability due to variation in storage, processing or cooking methods, nor for antagonisms

139	between different nutrients and/or non-nutritive substances in food. These methods may also be

140	limited in terms of accuracy, since they may rely either on recall (ffqs), present a high respondent

141	burden (food diaries), or represent an estimation (purchase data). In addition, dietary records and

142	questionnaires do not accurately capture supplement use in the elderly (28), which, research suggests,

143	may be substantial(29–31). Thus it is possible that reported average B-vitamin intake, at least in some

144	studies, may be misleading.

145	More important perhaps is the conceptual framework by which the reference guidelines seek to

146	specify deficiency prophylaxis. There may well be important differentials between levels of intake

147	associated with deficit symptom prevention and optimal metabolic status and function. Analyses

148	using additional biochemical measures have shown nutrient intake data to lack validity in

149	determining micronutrient status in elderly populations(32).

150	Sarcopenia appears to be a multi-factorial pathological process, which, although associated with

151	age, is not a de-facto outcome of ageing. Since B-vitamins are directly and indirectly involved in

152	the operation of an array of biological systems, and since these systems appear to be sensitive to

153	even relatively short-term deficiencies, vitamin contribution to the complex aetiology of sarcopenia

















156	FUNCTIONS AND THE EFFECTS OF DEFICIENCY

157	Important food sources of B1 include yeasts, whole-grain cereals (B-vitamin content being

158	concentrated in the outer germ layer of grains), nuts and legumes, pork meat and organ meat

159	(particularly the liver, kidneys and heart)(33,34). B1 is present in the human body in different forms.

160	The best characterization of B1 is as thiamin pyrophosphate (TPP) or thiamin diphosphate (ThDP)

161	in its twice phosphorylated, activated, cofactor form. Poorly characterized forms include adenosine

162	thiamin triphosphate (AThTP), thiamin monophosphate (ThMP) and thiamin triphosphate (ThTP).

163	As TPP, B1 is principally regarded as a key enzymatic cofactor in oxidative metabolism(35). More

164	specifically, B1 is known to function in 24 enzymatic reactions, most importantly pyruvate

165	dehydrogenase (for energy production via the Krebs cycle), transketolase (for lipid and glucose

166	metabolism, production of branched-chain amino acids, and production and maintenance of the







170	B1 is known to be directly associated with nervous system (NS) function, primarily as a result of

171	observation of rapid structural and functional declines in deficiency states and in alcoholism (37,38).

172	Whilst the sensitivity of the NS to B1 is largely attributed to the heavy reliance of this system on

173	oxidative metabolism(39), region-specific sensitivity to B1 deficiency has been observed in neuronal

174	tissues that have otherwise comparable metabolic profiles(40). This sensitivity may in part be

175	explained by the additional, non-coenzyme functions of B1, particularly as an antioxidant, i.e. in

176	relation to varying regional susceptibility/exposure to oxidative stress(41,42).

177	Chronic B1 deficiency is associated with several potentially life-threatening neurological disorders.

178	Whilst B1 deficiency is frequently associated with the central nervous system (CNS), the most

179	advanced neurological changes have been shown to occur in the periphery – particularly in the

180	lower limbs(43). This finding mirrors an aetiological feature of sarcopenia, for which muscle mass

181	and function in the lower limbs are relatively more compromised(44,45). Since muscle fibres function

182	within the context of motor units, such an overlap is unsurprising.

183	Early signs of B1 deficiency are cognitive decline, loss of appetite, weight-loss/loss of lean mass,

184	reduced walking speed, abnormal gait and muscle weakness/tremors(46). Though poorly delineated,

185	these symptoms are relevant and represent the least easily detected (by clinical appraisal) and most

186	likely manifestations of B1 deficiency in otherwise healthy elderly. B1 deficiency is being

187	increasingly associated with loss of vibratory sensation in the lower extremities(47), a higher

188	incidence of falls over time(48) and depression(49). A low B1 status is also increasingly implicated in














190	A number of different mechanisms have been put forward to explain neuronal loss/damage during

191	thiamin deficiency (TD). The mechanisms proposed relate chiefly to the reduced activity of B1-

192	dependent enzymes in mitochondria and include impairments in oxidative metabolism(52), and

193	mitochondrial function(53), resulting in inflammatory responses associated with microglial

194	activation, (54,55) increased production of reactive oxygen species (ROS),(56) and later, glutamate

195	receptor mediated excitotoxicity(57,58). These mechanisms have been elucidated through

196	investigations using cell lines, following/leading to observations of CNS damage during

197	experimental B1 depletion in animals.

198	In addition to providing mechanistic insight, these studies have elucidated important temporal

199	dimensions in TD, and suggest a need for further research into the effects of episodic and

200	cumulative sub-optimal B1 status in humans. For example, Ke et al. found that a moderate-low B1

201	intake in mice triggered an immune response, activating microglia and resulting in widespread loss

202	of neural tissue (29%) in B1-sensitive regions within 9 days of TD(54). Whilst intervention with B1

203	on day 8 of TD was shown to prevent further damage, the commitment of neuronal cells to







207	The UK NDNS reports that the average intake of B 1 exceeds the reference nutrient intake (RNI)

208	across all age groups(27). Audits in other European countries have largely produced similar findings.

209	However, recent large-scale, cross-European investigations have indicated important regional

210	variations(59,60). Other large scale and smaller scale studies of free-living elderly populations

211	demonstrate significant numbers who have inadequate intake (up to 60%)(61–64), possibly due to

212	more rigorous methodological approaches or biases resulting from the age-ranges selected,

213	socioeconomic or geographic factors(65). Inadequate intake in non-free-living elderly populations is

214	reported to be widespread in industrialized nations: between 33% and 94%(66–70). Where subject age

215	is reported as a continuum, B1 intake appears to be negatively correlated with this variable(47,71).

216	Interestingly, supplemental intake, which has been reported to make a major (>50%) contribution to

217	overall intake (72) is often not included in DI studies.

218	As with other B-vitamins, variation in the reported prevalence of deficiency is partly due to the use

219	of different referencing guidelines, e.g. minimum requirements vs. two-thirds of the RDA(21).

220	Furthermore, assessments of intake frequently do not take into account a potential relative deficit of

221	B1 induced by consumption of refined carbohydrates, which require B1 for their metabolism(39,73).

222	Storage, cooking methods and co-ingestion of foodstuffs such as alcohol, sulphites, tannins and o-
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224	content and bioavailability(75–77) are seldom considered. It is unsurprising therefore that studies

225	comparing assessments of intake with biochemical markers find little correlation, with one study

226	demonstrating biochemical deficiency (TPP effect >14%) in more than 50% of a sample who had

227	an intake exceeding guideline requirements (RNI)(78).

228	Biochemical data from elderly populations is scant and mainly related to specific pathological

229	states. Results from the UK NDNS indicate that less than 1.2% of the elderly are deficient in B1,

230	based on a measure of transketolase activity (TKA); erythrocyte transketolase activation coefficient

231	of >1.25(27). This cut-off point is less conservative than that suggested by other authorities,

232	including EFSA (>1.15)(79). Studies on free-living elderly populations, which employ a cut-off point

233	of >1.15 have indicated a greater prevalence of B1 deficiency: between 10 and 47%(29,32,48,80,81). The

234	reported range does not appear to be greater in non-free-living elderly populations. In view of these

235	findings, it is interesting to note that whilst most reports, including that of the UK NDNS, consider

236	‘the elderly’ as a single age bracket having reduced requirements, biochemical data indicate a





239	Guidelines for B1 intake in the UK currently indicate a requirement of 0.9mg/day and 0.8mg/day for

240	men and women aged ≥50 years, respectively(82). These represent the Reference Nutrient Intake

241	(RNI), and have largely been determined according to measures of minimum B1

242	requirements/1000kcal energy intake(82). Whilst these recommendations are safeguarded by

243	established minimum B1 requirements, associated urinary output measures for the prevention of beri

244	beri and/or signs of clinical TD, not enough consideration appears to have been given as yet to the

245	elderly in this respect, and only one of the studies referred to appears to have included elderly

246	participants. More importantly perhaps was the nature of this study: experimental

247	depletion/repletion of a small sample (n=21) of institutionalized male psychiatric patients(83). Given

248	the known association of neuropsychiatric illness with B1 status, a history of mental illness at study

249	baseline may limit the broader contemporary relevance of this work. On the other hand, this

250	research does present some interesting suggestions in that while small age-related differences in

251	glucose absorption rates were found, functional differences in B1 status (via lactate and pyruvate

252	accumulation) were in evidence according to younger-older subject status. The study does not,

253	however, go on to discuss any precise mechanistic role for B1 status to explain these observations.

254	In the absence of such, and given the limited scope of the measurements, derivation of age-specific

255	dietary requirements may be in need of review. Finally, it is interesting to note that the study found















257	Recommendations made by other major industrialized countries, including Germany, Switzerland,

258	Australia, New Zealand and the United States, are between 10 and 25% higher than the UK

259	guidelines(46,84,85). Part of this difference may be accounted for by use of different paradigms,

260	whereby guidelines are developed in relation to points of saturation rather than minimum

261	requirements for disease prevention. There is some epidemiological evidence to indicate that an

262	intake of B1 at a level of ~0.9mg/day appears to be sufficient to sustain a good level of health in

263	elderly Italian women(86), an observation-based indication of B1 sufficiency at a level 12.5% higher

264	than the UK RNI.

265	With respect to the use of the TKA assay as a reflection of B1 sufficiency it should be noted that in

266	the elderly: i) age-related reductions in TKA activity are known to occur (likely due to depressions

267	in apoenzyme levels and potentially confounding the interpretation(87); ii) prolonged B1 deficiency

268	also induces a lowering of basal and stimulated transketolase activities, possibly through the same

269	mechanism(88). Therefore the absence of baseline TKA data may be misleading with regard to

270	sufficiency. It is of note that syndromes of polyneuritis, as commonly observed in the sarcopaenic






273	FUNCTION AND EFFECTS OF DEFICIENCY

274	Important food sources of B3 include: yeasts, teas and coffees, whole-grain cereals, dark-green leafy

275	vegetables, poultry and meats, fish (especially varieties which have ‘red’ meat, e.g. tuna), nuts and

276	legumes and organ meat (in particular, the liver)(34,90).

277	Niacin (nicotinic acid), and its derivative nicotinamide, are principally understood as components of

278	the coenzymes nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide

279	phosphate (NADP+), which have related functions. NAD+ and NADP+, which may be reversibly

280	reduced to NADH and nicotinamide adenine dinucleotide phosphate hydrogen (NADPH), are

281	known for their role in energy metabolism: the transfer of hydride ions (H-) within dehydrogenase-

282	reductase systems. These two co-enzymes mediate, and have impact on, a wide-range of processes

283	within the body. These include, but are not limited to, calcium homeostasis(91), gene expression(92),





286	Potential relationship with sarcopenia

287	Chronic B3 deficiency (ND) is known to result in pellagra(97). Although the neurodegenerative

288	symptomology in pellagra is well established, the neuropathological component of pellagra (per se)













290	humans in the 1930s include the chromatolysis of motor neurons, beginning at the level of the CNS

291	(e.g. Betz cells in motor cortex)(98,99), with clear implications for neuromuscular function. With

292	regard to disease progression, human depletion studies have indicated that the clinical symptoms of

293	pellagra can manifest in subjects on a diet low in B3 (~4.3-5.7mg/day) and tryptophan (178-





296	Symptoms associated with B3 deficiency include neuromuscular deficits such as muscle weakness

297	and wasting, gait and truncal ataxia, peripheral neuritis, limb areflexia and myoclonus(102–104).

298	Although non-specific, our understanding of the early/less acute clinical manifestations of ND

299	largely derives from behavioural changes associated with a diminished metabolism and NS

300	dysfunction, e.g. anorexia, weakness, inactivity, a decline in nerve transmission velocities, fatigue,

301	anxiety, irritability and depression(105,106). It is interesting to note a degree of similarity between the

302	neurological and neuromuscular deficits observed in ND states and the frailty of sarcopenia. In this

303	connection, it is important to be aware that sub-acute ND is poorly characterized in the literature,

304	seemingly due to the variable and non-specific nature of associated symptoms.

305	Potential mechanisms for neuromuscular damage can be discerned from experimental depletion of

306	cellular NAD+ that induces oxidative damage and mitochondrial instability. Such models may be of

307	particular relevance since they mirror key processes underlying cellular senescence and which are

308	associated with the pathogenesis of sarcopenia(107).

309	NAD+ is a co-factor for poly-ADP ribose polymerases (PARPs), which carry out deoxyribonucleic

310	acid (DNA) base excision repair processes and / or mediate cell death in response to oxidative

311	damage, ischemia and excitotoxicity(108,109). When DNA damage is increased following ROS insult,

312	cytosolic NAD+ is rapidly depleted. Such events have been demonstrated to initiate PARP-mediated

313	apoptosis in myocytes in vitro, as well as in neurons, if NAD+ status is not restored within hours

314	(110,111). In terms of the precise concentration-effect relationship, it is noteworthy that PARP

315	complex formation appears to cease with only a 50% reduction in cellular NAD+(112). Importantly,

316	the administration of ‘supraphysiological’ doses of B3 (≥500mg/kg+), to allow for a surplus of

317	NAD+/NADP+, has been demonstrated to prevent these specific events and the subsequent loss of

318	neuronal tissue during experimentally induced ROS insult in vivo(113). Following on from this line

319	of enquiry, and since ROS production is known to increase with age along with mitochondrial

320	dysfunction, investigations aimed at re-examining requirements according to such parameters as the

321	maintenance of cellular NAD+ seem warranted.

322	A number of additional mechanisms by which low levels of NAD+ may contribute to cell death

323	have been identified and it appears the apoptotis inducing events following PARP induced NAD+













325	regard to the latter point, mitochondria are known to require relatively high concentrations of NAD+

326	to drive ATP production, and to re-coup NAD+ from reduced NADH formed during glycolysis (in

327	cytosol). Subsequently, low levels of NAD+ have been shown to result in a ‘cellular energy

328	crisis’caused by mitochondrial dysfunction. This dysfunction has been further shown to result in

329	mitochondrial depolarization and the release of mitochondrial Apoptosis Inducing Factor, as in

330	PARP-1 mediated cell death following NAD+ depletion(111). Though these effects have been

331	observed in neurons, which are highly glycolytic, they may also apply to muscle tissue, which

332	periodically enter phases of high glycolytic production of ATP.

333	In addition, Gomes et al. demonstrated in animal models that the age-related decline in nuclear

334	NAD+ induced pseudohypoxia by disrupting mitochondrial homeostasis through a shift in PGC-

335	1α/β-independent pathways associated with nuclear-mitochondrial communication (and secondary

336	to HIF-1α accumulation)(114). This communication change alters mitochondrial function through

337	loss of mitochondrial DNA coding for specific sub-units required for oxidative phosphorylation.

338	Since mitochondrial dysfunction is now well-established as one of the hallmarks of sarcopenia and

339	ageing in general, the maintenance of mitochondrial function should represent a fundamental

340	consideration in the establishment of nutritional requirements.

341	Gomes et al. demonstrated that normal mitochondrial function can be restored in ageing mice,

342	relative to young mice, simply by increasing cellular concentrations of NAD+ via normal dietary

343	means. This effect appears to be SIRT1 mediated. Since the sirtuin family of enzymes are also

344	NAD+ dependent, low levels of NAD+ have been shown to have a negative influence their

345	activities(115,116). The better characterized of these, SIRT1 and SIRT2, have been implicated in cell

346	survival (and human longevity) due to their role in the regulation of programmed cell death(117).

347	Importantly, recent experiments in mice have indicated that when NAD+ levels within the cell are

348	limited, the stimulation of SIRT1 in neuronal tissue can hasten action in apoptotic pathways.

349	However, when NAD+ levels are high, or with increasing concentrations of nicotinamide (a SIRT1

350	inhibitor), neuronal tissue has been observed to be protected from apoptotis inducing events(115).

351	Similarly, there is now good evidence to support the importance of maintaining cellular

352	nicotinamide and NAD+ concentrations in order to prevent SIRT2-mediated apoptosis(118).

353	There is evidence that age is an important determninant of cellular NAD+ levels. A recent study on

354	Wistar rats demonstrated that starting in adulthood, ageing is associated with a significant decrease

355	in intracellular NAD+ levels (p = <0.01), and a decrease in the NAD+:NADH ratio (p = <0.01)(119).

356	These changes have been shown to be consistent with increasing ROS production and DNA

357	damage, resulting in decreased SIRT1 (p = <0.01) and increased PARP (p = <0.01) activity, as well

358	as a decrease in ATP production (p = <0.01), indicating impaired mitochondrial function. This
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360	in cellular NAD+ levels in both men (p = 0.001; r = -0.706) and women (p = 0.01; r = -0.537)(120).

361	Interestingly, Massudi et al., found that the change in cellular NAD+ concentration over time was

362	consistent with the increased activation of PARP in men (p = <0.0003 r = -0.639) and a decline in

363	SIRT1 activity (p = <0.007), but not in women(120). These results demonstrate an increasing

364	requirement for NAD+ with age, and whilst the mechanisms for NAD+ depletion may appear to







368	There is a paucity of recent biochemical data on B3 status in the elderly (UK) population, and from

369	elsewhere in Europe and North America. This may be attributable to the relative difficulty in

370	assessment, with the urinary output of associated metabolites representing the only universally

371	accepted method. Subsequently, assessments of B3 status are widely based on intake.

372	The 2014 update to the UK NDNS suggests a mean intake of B3 above the RNI for all age

373	groups(27). Recent large-scale European and North American studies have recently suggested that

374	ND is not widespread in free-living elderly populations(121,122). Interpretation of such is difficult as

375	larger scale intake studies suggesting adequacy are often presented in terms of mean intake for an

376	entire cohort. whereas intake studies specifically focused on the elderly, have indicated that DI of

377	B3 in free-living elderly populations decreases significantly, typically between the ages of 50 –

378	90+(71,123,124). Intake data from institutionalized elderly populations in the Western world indicate a

379	broad range of inadequate intakes, between 0 – 26.7%(125–127)  It is important to note however that

380	intake data frequently does not correlate with biochemical determinants of status(128). Numerous

381	factors, including genetic variability(129), have been indicated in this regard. In addition, it should be

382	noted that the primary source of B3 for most populations is mature staple cereal grains, in particular

383	wheat and corn, which contain high concentrations of glycosides. These bond with B3 in a manner





386	The United Kingdom (UK) RDA (RNI) for B3 is 16mg/day and 12mg/day, for men and women

387	aged 50+, respectively(82). This determination is based on data from an early human depletion study,

388	indicating mean B3 intake requirements to i) to alleviate the clinical signs of pellagra, ii) to

389	‘normalize’ urinary output of N-methyl-nicotinamide and its downstream metabolite methyl-

390	pyridone carboxamide, whilst in energy balance(82). This recommendation, apparently derived from

391	the one study referenced (Hokwitt et al., 1956) is 5.5mg/1000kcal(131). The UK RNI is inclusive of a

392	10% coefficient of variation and yields an RNI of 16mg/day and 12mg/day for men and women













394	included in this RNI is the contribution of niacin derived from the endogenous conversion of

395	tryptophan to niacin in the ratio 60:1, giving a stated requirement for niacin or nicotinic acid

396	equivalents. Whilst it is suggested that tryptophan to niacin conversion alone may satisfy B3

397	requirements, based on assessments of dietary protein intakes(82), the conversion ratio is dependent

398	on the intake, and relative availability of, multiple nutrient factors, including the availability of all

399	other relevant co-factors (e.g. pyridoxine)(132). The study of Hokwitt et al. included only 3 elderly

400	subjects who were reported as sedentary(131). Taken together this gives limited scope to interpret






403	FUNCTION AND EFFECTS OF DEFICIENCY

404	B6 is naturally abundant in meat and poultry, including lean muscle meat, and can also be found in

405	nuts and legumes and in fortified foods (133). B6 refers to a class of nitrogen-containing compounds,

406	which comprise pyridoxine, pyridoxamine, pyridoxal and their phosphate derivatives. In

407	physiological terms, B6 is principally understood to function in amino acid metabolism(134) as the

408	cofactor pyridoxal-5-phosphate (PLP) and is associated with a wide range of physiological

409	processes, most of which are biosynthetic, being (for example) involved in the synthesis of

410	heme(135), several neurotransmitters, including serotonin(136), purines(137), several hormones,

411	including steroid hormones(138), and fatty acids(139). Clinical B6 deficiency (PD) may therefore





414	Potential relationship with sarcopenia

415	Clinical indicators of marked PD in adults are largely neurological and epithelial/mucosal

416	aberrations, which mimic deficiency of other vitamins within the B-complex. The majority of

417	neurological symptoms (particularly in cases of mild PD, which is more commonplace) appear to

418	affect the peripheral nervous system (PNS) and are associated with loss of motor function(140).

419	These include, numbness/paresthesia in the extremities which may progress to a loss of distal

420	sensation, motor ataxia, weakness and loss of deep tendon reflexes(141–143). Non-specific symptoms

421	such as nausea, GI disturbances, vomiting, and mood/behavioral changes (e.g. anorexia, apathy,

422	depression and fatigue) have also been described.

423	Work in this area has been carried out with rats, with one seminal investigation demonstrating

424	axonal degeneration akin to Wallerian degeneration, as primary in the development of peripheral

425	neuropathy characterized by ultrastructural changes, including swelling of local (axonal)
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427	within neurons(144). Pathologic disturbances have also been noted in and around Schwann cells and

428	within the nucleus(145). Motor neurons, and in particular those which feed more distal muscles,

429	appear most affected by this process, which leads to an increasing denervation of muscle fibres(146).

430	These findings are consistent with case studies of isoniazid (isonicotinic acid hydrazide, a B6

431	antagonist) toxicity in humans, in which motor symptoms are reportedly predominant(140).

432	Interestingly however, the morphological changes discussed earlier have been shown to be present

433	in cases without any clinical signs of neuromuscular dysfunction. Therefore, studies in which

434	isoniazid has been administered to animals with the aim of developing an understanding of early

435	changes in neuropathies may provide valuable insight. Noting from previous studies that functional

436	disturbances take 7-8 months to manifest(147), Hildebrand et al. administered isoniazid to rats for 3-

437	13 days and found a significant loss of neural tissue, a reduction in conduction velocity and wide-

438	spread muscle atrophy (by day 3), followed by extensive myelin disruption, fragmentation of

439	intramuscular nerve fibres and a reduction in muscle action potential (by day 10)(148). Whilst

440	reactive collateral branching of motor fibres appeared to be sufficient to normalize most of the

441	assessment parameters 37 days after ceasing the intervention, a significant proportion of the damage

442	to peripheral nerve fibres was still apparent and the pattern of atrophy in large-group muscle fibres

443	showed no improvement(148). At present a mechanistic model for these observations has not been

444	established, and whilst it is difficult to exclude the potential contribution of direct toxicity from

445	isoniazid on nerve axons, it seems probable that B6 deficiency is indeed implicated. With regard to

446	muscle atrophy, studies elsewhere have observed reduction in skeletal muscle protein synthesis in

447	rats with a marginal B6 intake(149).

448	The effects of a chronic, sub-optimal B6 status in the elderly are poorly understood.

449	Epidemiological associations between low B6 intake and frailty/disability are however widely

450	reported – particularly in women. Amongst these, a prospective (3 years) study of 643 free-living
451	
452	elderly (≥65 years) women, into the possible relationship between specific micronutrient status

453	(biochemical) and risk of developing disability, found that those with a plasma PLP level of

454	>4.4ng/ml (17.8nmol/L), had a significantly greater risk of developing disability (HR 1.31; 95% CI,

455	1.03-1.67, p = 0.02) than those with PLP levels exceeding this threshold(150). In direct relation to

456	sarcopenia, the Maastricht Sarcopenia study, which comprised 227 free-living elderly (>60 years)





459	In this regard, it is interesting to note that inadequate B6 intake has been linked with an increased

460	risk of osteoporotic fractures and related falls. Since osteoporotic fractures are associated with

461	concurrent sarcopenia and since the pathogenic mechanisms underlying both sarcopenia and













462	holistic approach. With this in mind, it is important to note the likelihood of gender based

463	differences here, since the risk / progression of osteoporosis is more marked in older women. This is

464	attributed to the relative deficit in bone mineral homeostasis incurred as a result of the decline in the

465	oestrogen axis post-menopause(153). To illustrate, a large-scale (n=63,257) prospective investigation

466	(follow-up time ~13.4 years) into the association between dietary B-vitamin intake and the risk of

467	hip fracture in men and women aged 45-74, found a statistically significant negative correlation

468	between the incidence of hip fractures and energy-adjusted B6 intake, in women (p = 0.002) (Dai et
469	
470	al., 2013). Women whose B6 intake represented the lowest quartile (mean pyridoxine ≤1.30

471	mg/day) had a 22% increased risk of hip fracture, relative to those in the highest quartile (mean

472	pyridoxine ≥2.03 mg/day) (HR = 078, 95% CI = 0.66-0.93). This is consistent with other similar

473	investigations, including the Rotterdam study, which found women in the highest quartile to have a

474	significantly reduced risk of fragility fractures (HR = 0.55, 95% CI = 0.40-0.77, p = 0.004) and non-

475	vertebral fractures (HR = 0.77, 95% CI = 0.65-0.92, p = 0.005)(155). Importantly, the same study

476	identified a significant risk-reduction following supplementation with B6, which took place

477	independent to any change in BMD. Whilst the specific mechanism(s) underlying this effect are at

478	unclear at present, it is known that B6 is required for the maintenance of the collagen matrix

479	supporting bones(156). Subsequently, an increased rate of collagen synthesis has been suggested as

480	one potential mechanism for this effect(155).

481	Elsewhere, studies which have observed a correlation between hyperhomocysteinemia (hhcy) and a

482	decline in BMD, as well as deleterious architectural changes, have put forward the b-vitamin

483	deficiency (B6, B9, B12) induced build-up of this metabolite as another possible mechanism, in

484	addition to the direct role these b-vitamins play in bone metabolism(157,158). A recent review of this

485	area suggests that while these and other B-vitamins (e.g. B1) are clearly involved in bone

486	homeostasis, clinical trials are needed to determine the efficacy of supplementation protocols(159).

487	Whilst such data help inform the relation between poor B6 nutrient status and frailty, evidence for







490	The UK NDNS suggests a mean intake of B6 above the RNI for all age groups(27). However, the UK

491	RNI is lower than those established by other authorities such as EFSA(160). Data from other

492	industrialized nations suggests considerable variation in intakes. Whilst some large-scale

493	investigations report adequate intake of B6 amongst free-living elderly populations, these often

494	contradict smaller scale studies, which typically employ more time-intensive methods and suggest a













496	reached epidemic proportions in the total US population (affecting 71% and 90% of men and

497	women, respectively) and this was significantly associated with ageing (p<0.001)(163). In fact, a

498	significant age-related decline in intake is almost always observed where an extended age range is

499	considered(31,72,164–166). Inadequate intake is more consistently reported in non-free-living elderly

500	populations(66,167,168). This includes an extensive, cross-sectional assessment of B6 intake across 11

501	long-term residential facilities in Canada, which reported inadequate intake in more than 50% of

502	the total participant group(125).

503	As with other B-vitamins, data on intake is typically revealed to provide a more optimistic picture

504	than biochemical data(169). Amongst these, Kjeldby et al. were able to identify a biochemical

505	deficiency (using PLP values) in up to 49% of an elderly population with an ‘adequate’ (mean)

506	intake(170). Past NDNS (1994-95) had indicated PD (plasma PLP <30nmol/l) to be endemic in the

507	UK elderly population, being 49% in community-dwelling- and 75% in the institutionalized elderly

508	(>65yrs)(171). The 2014 NDNS report – the first since 1999 to include biochemical data on the

509	elderly – suggests no indication of deficiency despite using the same measures(27). Only the mean

510	value for the entire cohort is provided however. Elsewhere, the range of reported prevalence of PD

511	according to biochemical indices is typically between 26-59% in free-living(29,32,81,172) and

512	5.3-49%(126,170) in non-free-living elderly populations in industrialized nations.

513	Assessment according to functional biomarkers, such as erythrocyte aspartate aminotransferase

514	activity (EAAA), and levels of circulating metabolites such as cystathionine and taurine, which are

515	known to build-up in the deficient state, appear to indicate an even greater prevalence than PLP

516	measures(137,173). Review data suggests a combination of functional biomarkers are required for

517	assessments in the elderly, due to confounders such as changes in renal function, increased







521	The RDA (RNI) for B6 intake in the UK is set at 1.4mg/day and 1.2mg/day for men and women
522	
523	aged ≥50 years, respectively(82). This determination is based on a small number of studies focused

524	on functional parameters related to protein metabolism: namely changes in tryptophan and

525	methionine metabolism in response to variation in protein intake, and during depletion(82). The RDA

526	(RNI) is based on an assessment of the quantity of B6 required to metabolize recommended (or

527	slightly greater) levels of protein intake (~50-150g protein/day) whilst maintaining protein

528	homeostasis, according to select outcome measures (e.g. urinary output of xanthurenic acid, XA).

529	The RDA is therefore not in fact absolute, and is delineated as 15µg/g protein(82). Even if these













530	be issues with respect to their wider application, since determinations are based on small sample

531	groups (n=6-13) comprised of young men (≤31 years)(175–178).

532	Whilst it is true that elderly populations are widely-reported to have a reduced intake of protein, an

533	increased requirement for protein in elderly persons (1-1.2g/kg/day) is now being recognized(179,180).

534	Subsequently, there is a growing impetus to increase protein intake in this population. On this basis

535	alone, the existing guidelines for B6 (although not absolute) may be outdated. The extent of this is

536	perhaps best elucidated by the fact that the 25-50% increase in protein requirements not reflected in

537	the RNI for B6 represents more than the difference between the current estimated average

538	requirement (EAR) and RNI, implying that >50% of elderly persons would not be able to match B6

539	requirements with protein intake. It should also be noted that recent investigations do not in fact

540	support any association between protein intake and B6 status in both elderly men and women(172).

541	Data from more recent depletion/repletion studies in the healthy elderly indicate an extended

542	physiological range of function for B6 that is observed in response to increased levels of intake

543	(15µg/kg body weight/day – 50mg/day). Evidence for this includes a significant decrease in urinary

544	output of XA post tryptophan loading (5g) in elderly women and other direct outcomes in immune

545	system function, including lymphocyte proliferation in response to peripheral mitogens(181). Another

546	study examined requirements in the elderly in relation to normalizing multiple associated

547	physiological outcomes, including EAAA and output of XA(182). These authors took into account

548	different levels of protein intake and suggested that the minimum requirement for B6 in the elderly

549	is 1.96 and 1.90 mg/day, for men and women, respectively(182). Several noteworthy studies indicate

550	still greater requirements. Amongst these, Morris et al. differentially examined (for the first time)

551	the correlation between B6 intake and plasma PLP levels, using data from a US population-

552	representative sample of over 6000 participants in the National Health and Nutrition Examination

553	Survey (NHANES; 2003-2004). Their study also examined the possible relationship between

554	plasma PLP and homocysteine (hcy). The findings indicated that the elderly have a markedly

555	increased requirement for B6: an intake of 3-4.9mg of vitamin B6/day was needed simply to avoid a

556	low plasma PLP (<20nmol/L) and hhcy(169). More importantly perhaps, B6 requirements were not

557	found to be reduced in elderly persons with a low protein intake (54g/day)(182), which may suggest
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562	Important sources of B9 include green leafy vegetables, citrus fruits, nuts and legumes, and fortified

563	foods(133). Folate content in lean muscle meat is typically low, but high in organ meats, particularly

564	the kidneys and in the liver(183). Folate (B9) describes collectively both natural folates and the

565	synthetic folic acid/pteroylmonoglutamic acid (PTeGlu), which are functional within the body as

566	the cofactor tetrahydrofolate (THF). THF has important roles in one carbon metabolism: as a

567	methyl group donor. The first step in the methylation cycle, in which THF is transformed into

568	5,10-methylene-THF (5,10-MTHF), is catalyzed by the PLP-dependent enzyme, serine

569	hydroxymethyltransferase(184). This highlights the functional interdependence of B-vitamins. B12 is

570	of particular interest in this regard, since there is considerable functional overlap with B9 – such that

571	one being in sufficient supply may mask a functional deficiency of the other, e.g. prevent

572	macrocytosis(185). This can have implications for elderly populations which are not routinely

573	screened, since the neurological effects of B12 deficiency are irreversible at an advanced stage when

574	clinical symptoms are manifest. It is also well established that B12 deficiency leads to a functional

575	B9 deficiency (FD)(186). Whilst the precise mechanism is as yet unclear, the subsequent reduction in

576	the activity of (the B12-dependent enzyme) methionine synthase is known to result in a build-up of

577	5-methyltetrahydrofolate (5-MTHF)(187), and therefore represents a popular hypothesis(188). In all,





580	Potential relationship with sarcopenia

581	Whilst anaemia is the traditional association, FD may compromise the function of any system

582	dependent on one-carbon metabolism, or affected by concentrations of associated metabolites.

583	Subsequently, B9 deficiency may contribute toward a range of pathologies, particularly if prolonged

584	and in the presence of aggravating factors such as inadequate levels of B12. Determination of the

585	extended role of B9 in human health may be difficult in clinical terms since the effects of marginal

586	deficiency may be subtle or so indirect as not to be obviously tied to B9 status.

587	One of the established pathophysiological outcomes of B9 deficiency, with possible pertinence to

588	sarcopenia, is the build-up of homocysteine (hcy): hyperhomocysteinaemia.

589	Hyperhomocysteinaemia, which is prevalent in the UK elderly population(189), has been shown both

590	epidemiologically and experimentally to be tied more closely to FD than to other methyl group

591	donors such as B12(190,191).

592	With regard to possible long-term effects, large-scale longitudinal investigations (>15 years) have

593	identified plasma hcy as an independent risk factor for future incidence of major, age-related,

594	neurodegenerative disease(192,193). Similarly, studies into the long-term relationship between hcy and

595	physical function have identified significant associations between modest elevations in plasma hcy













597	effects on skeletal muscle are relatively unexplored, using both cross-sectional and prospective data

598	obtained from 1,301 elderly (>65yrs) participants in the Longitudinal Ageing Study in Amsterdam

599	(LASA), Swart et al. have demonstrated an association between elevated hcy and reduced grip

600	strength in men, and increased functional limitations in both men and women(196). Elevated (total)
601	
602	hcy (≥15µmol/L) and B9 (but not B12) deficiency (<3ng/mL) have also been associated with

603	markedly increased risk of brain atrophy(197).

604	Whilst the authors of these studies suggest hcy to be a causal factor and not a marker in

605	neuromuscular decline, there is a dearth of mechanistic enquiry into this topic, particularly in

606	relation to neuromuscular/musculoskeletal decline. Several plausible mechanistic links have,

607	however, been demonstrated, for example, hcy induction of neurotoxicity in animals. It is notable

608	that neural tissue appears to be more sensitive to elevations in hcy than endothelial smooth muscle

609	cells(198), on which most research in this field has been focused. Relevant mechanisms in the CNS

610	include: the inhibition of acetyl-cholinesterase activity (involved in neurotransmitter breakdown) in

611	rats, N-methyl-D-aspartate (NMDA, glutamate) receptor interaction induced excitotoxicity in

612	neurons, and region-specific inhibition of Na+/K+-ATPase activity in the brain (resulting in inability

613	to maintain cell polarity)(198). In the PNS, hcy-NMDA receptor interaction has additionally been

614	linked (in mice) to increased sensitivity to oxidative -stress-induced inhibition of neurotransmitter

615	release and associated loss of cell integrity at the level of the neuromuscular junction(199), as in

616	motorneuron disease. Motorneuron disease is loss of motorneurons so naturally there is

617	degeneration of the neuromuscular junction.

618	Other mechanisms include the progressive depletion of NAD+ in rats, (secondary to DNA strand

619	break induced increases in PARP activity), subsequent mitochondrial dysfunction, and the

620	activation of caspase-induced apoptosis(200). This is in accord with findings elsewhere (in rats),

621	which demonstrate that the selective inhibition of PARP not only prevents hcy-induced damage, but

622	improves the condition of other tissue types(201). B9 supplementation has proven efficacy in this

623	regard: in addition to reducing hcy-associated PARP activity and inhibiting caspase-induced

624	apoptotic pathways, treatment with B9 but not B12 has been shown to increase expression of the

625	anti-apoptotic B-cell lymphoma protein Bcl-2. In addition, enhanced B9 supply inhibits expression

626	of tumour necrosis factor (TNF-alpha), induces nitric oxide synthase and supresses the activation of

627	glial cells in the CNS(202). These effects have been demonstrated in knockout models in mice that

628	mimic action of a common genetic variant in humans that results in amyotrophic lateral sclerosis, a

629	neurodegenerative condition in which elevated hcy is associated with the loss of motorneurons.

630	Stable isotope studies have provided valuable insights into the metabolism and relative

631	bioavailability of synthetic PTeGlu, compared to naturally occurring folates. In humans, as well as
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632	with conversion to the naturally occurring THF(203,204). In this connection, it is important to note that

633	the enzyme dihydrofolate reductase, which is expressed in the liver, and which is required for the

634	conversion (reduction and methylation) of PTeGlu into THF, is relatively limited in its activity(205).

635	This has led some to suggest that PTeGlu is therefore less biologically active than naturally

636	occurring folates. Also, due to the low rate of conversion, PTeGlu supplementation can result in

637	high concentrations of this circulating metabolite and potentially distort the accuracy of the

638	assessment of B9 status. Certainly the use of PTeGlu as a ‘reference folate’ in studies of folate

639	bioavailability has been questioned(204).

640	B9 has both a direct and an indirect role in DNA synthesis, methylation and repair processes,

641	principally due to its function as a cofactor for specific enzymes known to be involved in the

642	relevant pathways. Most notably, the (5-10-methylenetetrahydrofolate) folate-dependent

643	thymidylate synthases are known to catalyse the conversion of uracil into thymine(206).

644	Correspondingly, low intracellular concentrations of 5-10-methylenetetrahydrofolate have been

645	shown to result in a build up of uracil, an imbalance of the cellular deoxyuridine

646	monophosphate/deoxythmidine monophosphate ratio, and the DNA polymerase-associated, mass

647	misincorporation of uracil into cellular DNA(207–209). Emerging evidence suggests that this

648	frequently overlooked effect of B9 deficiency is implicated in increased DNA deletions,

649	chromosomal instability and damage to factors maintaining nuclear integrity(208,210–212). Although

650	currently this phenomenon has primarily been studied in relation to carcinogenesis, tissue-wide





653	The tissue-specific effects of this phenomenon have not yet been comprehensively delineated and

654	the possible impact on the nervous system and, in particular, the musculoskeletal/neuromuscular

655	system has not been explored in humans. This may represent an oversight, since animal studies

656	suggest potentially severe consequences. With regard to the nervous system, where more research is

657	in evidence, the dysregulation of the aforementioned pathway has been associated with

658	neurodegenerative and neuropsychiatric dysfunction(213). Knock-out models in mice have indicated

659	impaired uracil repair and impaired DNA glycosylase activity, secondary to B9 depletion that

660	resulted in moderate deficiency in this vitamin. Overall in this situation, there is promotion of

661	neurodegenerative processes resulting in neuronal death and an inhibition of neurogenesis,

662	associated with a region-specific reduction in brain-derived neurotrophic factor and glutathione(213),

663	and nerve growth factor(214). Duthie et al. have further highlighted the relative contribution of B9

664	deficiency, having observed that (moderate) FD, and not an inadequate status of other methyl-

665	donors with overlapping functions (e.g. choline and methionine), leads to progressive strand-













667	shown to result in an increased frequency of large-scale deletions in mitochondrial DNA in older

668	rats (1 year), compared to young weanling controls(215). Interestingly, whilst this effect appears to be

669	modulated by age, the association is lost following B9 repletion; uracil levels in DNA are





672	Animal studies into the musculoskeletal effects of the mass misincorporation of uracil into DNA are

673	in shortfall. In addition to non-tissue-specific risks to myocytes, chromosomal instability would

674	likely interfere with the formation of new myonuclei, which are required in the repair of skeletal

675	muscle cells(216) and to facilitate muscle hypertrophy in animals(217) and humans(218,219). The latter

676	association may be interpreted within the context of the myonuclear domain theory namely that

677	additional mynucleii are required to facilitate hypertrophy(220). In addition to compromising muscle

678	repair processes, e.g. following injury/extended bed rest, such a phenomenon may also compromise

679	the prophylactic/therapeutic benefit of exercise/movement as a stimulus for increased muscle

680	mass/strength. Damage to mitochondrial DNA within muscle fibres / cells is also likely to represent





683	The UK NDNS suggests a mean intake of B9 close to or above the RNI for all age groups(27). Data

684	from other industrialized countries typically suggest a high prevalence of inadequate intake, with

685	some reports ranging as high as 37-100% in both free-(23,221–224) and non-free-living elderly

686	populations. Over time, there seems to be a reduction in reported prevalence of inadequate B9 intake

687	in community-dwelling elderly populations, likely due to the emergence of functional foods and

688	food-fortification initiatives, but also in part due to the popularization of vitamin supplementation in

689	the general population(225), particularly in Europe. Data from the European Nutrition and Health

690	Report 2004, indicates B9 intake to be below acceptable levels across Europe(60).

691	The reported prevalence of biochemically determined FD typically ranges from 0-23.5%(226–229) in

692	free-living elderly populations and 5-68% in non-free-living/sick elderly populations(125,167,230,231) in

693	industrialized nations. It is again difficult to extrapolate from these findings due to the differences

694	(unknown or otherwise) in sample populations, reference parameters and methods of assessment. In

695	particular, the percentage of participants with polymorphisms affecting the methylene

696	tetrahydrofolate reductase, MTHFR gene is almost always unknown. The 2015 supplementary

697	report on the UK NDNS presents an interpretation of serum and erythrocyte folate levels according

698	to thresholds used by the World Health Organization (WHO) (<10nmol/L and <340nmol/L,

699	respectively)(232). This assessment finds the prevalence of FD in the UK elderly population (>65
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701	and 10.8% in women, when determined by erythrocyte folate levels(232). Whilst this data does

702	present evidence for/against potential age-related differences in B9 status for the over 65s, similar

703	investigations, which differentially assessed the over 65s, suggest the prevalence of deficiency in

704	this age-group increases significantly with age(233). It should be noted that supplement users were

705	not excluded from the NDNS sample population, and as with other B-vitamins, supplemental B9

706	intake is often found in sample populations with a low prevalence of FD(126,234) and this likely

707	distorts perception of dietary adequacy across a given population.

708	Metabolic markers of B9 status (e.g. homocysteine) are rarely employed in the assessment of

709	prevalence, despite indications of greater sensitivity in terms of detecting deficiency and typically

710	translating into marked increases in reported deficiency prevalence(235). It should be noted that past

711	national surveys, such as the 1994-95 sample assessed by the Ministry of Agriculture, Fisheries and

712	Food (MAFF), reported hyperhomocysteinaemia to be endemic in the British population(236). The

713	same report, which distinguished between free-living and institutional elderly populations, found







717	The RDA (RNI) for B9 in the UK is 200µg/day for both men and women aged 11+(82). As such, the

718	UK RNI for B9 represents one of the lowest amongst EU member states(128). The UK RDA is based

719	on several considerations. Firstly, the lower reference range is based on the quantities of PTeGlu

720	shown simply to reverse the signs of acute FD (megaloblastic anaemia), following experimental

721	depletion in i) an undefined sample(237) and ii) in a sample of 7 moribund cancer patients(238). Whilst

722	it is not even possible to comment on the sample population for the first study, determining

723	requirements through study of advanced stage cancer patients is problematic as derangements in





726	The determination of the upper reference ranges (RNI) for B9 are based on findings of adequate

727	liver B9 stores (>3µg) following post-mortem analysis of 560 Canadian samples, which represent a

728	heterogeneous sample(239). Since DI is not included, the results are contextualized (by COMA) by

729	allusion to an altogether separate investigation reporting a mean dietary B9 intake of 150-

730	200µg/day, and adequate erythrocyte B9 levels (>150µg/ml), in ~90% of a 1978 sample of the

731	Canadian population(240). COMA attempts to establish the relevance of this data to the UK

732	population through reference to ‘comparable’ median intakes in 1990(241). This is a rather indirect

733	estimate of requirements. Additionally, it was noted in the said report, and in a subsequent analysis













735	observed in 35% and 47% of men and women, and so represented the most widespread deficiency

736	of a nutrient known(242).

737	Elderly people have been shown to be more sensitive to marginal FD and relatively less responsive

738	to repletion than younger adults(243), particularly when more rapidly responding biochemical

739	parameters such as changes in DNA methylation are used in assessment(244). Other such parameters

740	indicate even higher requirements still. Amongst these, hcy has been observed not to reach its nadir

741	until an intake of 400µg/day has been achieved(245).

742	Finally, and as COMA later acknowledges, intake is typically observed to decline with age and B9

743	status is further affected by age-associated medical conditions, and associated medications(82).

744	Common examples include: non-steroidal anti-inflammatory drugs (NSAIDs)(246), H2 receptor

745	antagonists, antacids, proton pump inhibitors(247), insulin mimetics (biguanides, e.g. metformin)(248),

746	a wide-range of commonly prescribed antibiotics (e.g. amoxicillin)(249), bile acid sequestrants

747	(cholestyramine and colestipol)(250) and potassium-sparing diuretics (e.g. triamterenes)(251). Taken








751	FUNCTION AND EFFECTS OF DEFICIENCY

752	Since B12 is synthesised by bacteria living in the GI tracts of animals(252), sources include all animal

753	produce, to a lesser extent eggs and dairy produce, and fortified foods(253). Unlike other B vitamins,

754	B12 is stored in relatively large quantities in the liver(183).

755	Cyanocobalamin, or cobalamin (B12) forms the central component of the two corrinoid coenzymes,

756	methylcobalamin and S-adenosyl-cobalamin (cobamamide), which are unusual in that they are

757	thought to have limited functions within the body. Methylcobalamin is known to be required for the

758	methylation of homocysteine to produce methionine by way of methionine synthase(254). S-

759	adenosyl-cobalamin is required for the catabolic isomerization of methylmalonyl-coenzyme A

760	(CoA) into succinyl-coA by L-methylmalonyl-CoA mutase(255). Inadequate B12 intake therefore

761	results in a build-up of homocysteine and methylmalyonyl-CoA. Finally, low levels of B12 are also

762	known to result in a build-up of glycine, since B12 is required for the synthesis of porphyrin rings

763	from glycine and succinyl-CoA(256). The build-up of these metabolites results in a shortfall in

764	methionine and related upstream products such as S-adenosyl methionine, which carry out a broader

765	range of functions. Therefore, despite being involved in a limited number of reactions, the effects of

766	B12 deficiency are extensive, affecting multiple systems. The manifestations of deficiency may be













768	anaemia, which typically affects the elderly, is aetiologically distinct from megaloblastic anaemia,





771	Potential relationship with sarcopenia

772	In terms of neuromuscular dysfunction, B12 deficiency (CD) is associated with sub-acute combined

773	degeneration of the spinal cord and polyneuropathies. Histopathological findings from post-mortem

774	examinations indicate that CD results in extensive demyelination in the CNS – most prominently in

775	the spinal cord – although focal demyelination is also notably apparent in the brains white

776	matter(258–260). Demyelination has also been observed in the PNS, along with signs of significant

777	damage to nerve fibres, most notable of which is axonal degeneration in distal afferent fibres of





780	Clinically, B12 deficiency is associated with an extensive range of neuromuscular symptoms, which

781	become more severe as deficiency progresses, including paraesthesia, numbness in the trunk,

782	muscle weakness, abnormal reflexes, tendon jerks, spasticity, gait ataxia, myelopathies and

783	myeloneuropathies(263–266). Although CD is primarily associated with macrocytic anaemia, it is

784	noteworthy that neuromuscular symptoms, such as gait ataxia, represent common clinical

785	associations and mark the earlier stages of deficiency. These symptoms are primarily connected

786	with the loss of sensory rather than motor-unit function(264,267), specifically a decline in

787	proprioceptive, vibratory, tactile and nociceptive sensation. CD has also been shown to have a





790	Given the extent of neuromuscular dysfunction observed in CD, it is unsurprising that recent studies

791	have found significant associations between B12 status and frailty in old age. Amongst these,

792	Matteini et al. recently observed a 1.66-2.33× greater risk of frailty (p≤0.02) in elderly Caucasian

793	women with elevated methyl-malonic acid (MMA)(269). Whilst not all studies report such an

794	association, this again appears to be explained largely by use of different parameters and cut-off

795	points, as indicated in a recent study by Oberlin et al(270). Oberlin et al. carried out a retrospective

796	examination of data on 3,105 elderly persons (≥60 years) from early NHANESs (1999-2002), for

797	which multiple measures of B12 status were employed(270). They found that CD was significantly

798	associated with a much greater range of disabilities (e.g. in social and leisure activity, in mobility

799	etc.) when based on functional biomarkers and/or higher-cut-off points for serum cobalamin

800	(cbl)(270). The inconsistency between cbl values and the functional outcomes of B12 status have been
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802	Although investigations into the long-term effects of B12 supplementation in the elderly do not

803	appear to have produced clinically significant outcomes that directly relate to sarcopenia (e.g. time

804	to/number of falls, muscle mass and strength), there has been indication of improvements in more

805	general measures of physical function, such as walking speed (cumulative OR = 1.3, 95% CI =

806	1.1—1.5), which may indicate improved neuromuscular interactions(273). A realistic approach to

807	future research may utilize B12 data in conjunction with the many other known factors and co-

808	factors involved in neuromuscular structure and function – particularly amino acids associated with

809	muscle anabolism, such as leucine.

810	Indirect negative outcomes for neuromuscular function are also apparent. Amongst these, B12 status

811	(as well as that of B6) has been significantly associated with length of stay in rehabilitation

812	following injury(230), which in turn was related to a decline in both muscle mass and function –

813	muscle cachexia(9,274). The relationship between mood disturbances (e.g. depression)/neurocognitive

814	decline related to CD(266,275,276) and the development and progression of sarcopenia requires further

815	investigation since these are increasingly being established as significant contributors(277,278).

816	Finally, it is interesting to note that a recent study by Veerlan et al. (2015) found intakes of B12 to be

817	22% lower and serum cobalamin (cbl) to be 15% lower in a sample of people with sarcopenia





820	The UK NDNS suggests a mean intake of B12 above the RNI for all age groups(27). This is

821	consistent with other large scale pan-European studies on free-living populations which report mean

822	intake(59). However, as demonstrated in a recent systematic review and pooled analysis of

823	observational cohort and prospective studies of intakes in the elderly (>65 years), even though mean

824	reported intakes may be above the RNI, a large percentage of people (16-19% in the case of B12)

825	had an intake below the UK RNI/EU EAR(64). Inadequate intake is reportedly even greater in non-

826	free-living elderly populations (>65 years) across Europe and other industrialized countries,

827	particularly in the lower socio-economic strata and amongst migrants(29,167). There is indication that

828	a further 20-30% would be deficient if not for supplementation(29,280). In any case, intake in the

829	elderly is unlikely to translate to metabolic sufficiency in many cases due to poor absorption

830	associated with the combined issues of hypochlorhydria(281), gastritis and diminished intrinsic factor

831	production(282–285), as well as the widespread use of antacids(18,286).

832	As for other B-vitamins, B12 status has been shown to decline significantly with advancing

833	age(81,233). This finding is confirmed with respect to vitamin B12 in a study of an elderly population
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835	By measure of serum cbl, the UK NDNS(27) has indicated that 5.9% of elderly men and women are

836	deficient (<150 pmol/L) in B12. Although varied, estimates of the prevalence of CD from elsewhere

837	in Europe tend to be much higher, ranging from 10-40% for both community-dwelling and

838	institutionalized elderly populations(266,284,288–292). These typically use higher cut-off points and

839	other/additional, functional measures that have been shown to demonstrate greater sensitivity(292).

840	To illustrate the extent of the potential discrepancy, 12% of community-dwelling elderly in the

841	Framingham Study were identified as B12 deficient according to serum cbl; however, follow-on

842	investigations identified a further 50% of the sample (having elevated serum MMA) to be deficient

843	metabolically(235). Similarly, Morris et al. identified a further 15% of the NHANES 3 sample

844	population as being deficient when MMA was used as the criterion instead of serum cbl(293). Also

845	holo-transcobalamin (holoTC) has been shown to demonstrate even greater sensitivity than serum

846	cbl(294,295) and MMA(296), particularly in older populations(297). Due to the lack of clear reference





849	B12 is distinct from other B-vitamins in that, under normal conditions, there is a physiologically

850	significant bodily store, with estimates ranging from 2-3.9mg, most of which appears to be in the

851	liver(298,299). For this reason, and since the neurological effects of CD cannot be reversed, human

852	depletion studies have never been carried out.

853	The RDA (RNI) for B12 in the UK is 1.5µg/day for both men and women aged 15+(82). Excluding

854	Ireland, this value represents the lowest RNI in Europe(128), and stands in sharp contrast to the DGE

855	guideline, for which the RNI is set at 3µg/day(300), and the EFSA guideline of 4µg/day(301). EFSA,

856	which has based its recommendation on mean intakes associated with normal ranges of circulating

857	functional markers (MMA, total homocysteine – tHcy, serum cbl and holoTC), in fact reports that it

858	is intakes between 4.3-8.6µg/day that are associated with these values(301). This is consistent with a

859	recent, comprehensive analysis of B12 status alongside intake in Danish post-menopausal women,

860	which considered serum cbl, MMA, holoTC, trans-cobalamin (TC) saturation (holoTC/total TC)

861	and tHcy, as well as potential absorptive complications(280). It was found that an intake of 6µg/day

862	was required to normalize all parameters in persons with normal absorptive capacity(280). Follow-up

863	investigations into requirements in adulthood (18-50 years) have likewise suggested an increased

864	requirement of between 4-7µg/day, even in healthy persons(302).

865	The UK recommendation is based on an assessment of the requirements for the prevention of

866	megaloblastic anaemia as indicated by: i) a small number of intake studies on narrowly defined

867	groups of vegan/vegetarians in Sweden, Australia and South Asia; and ii) the haematological













869	There appear to be several limitations to the appropriateness of this data in determining the RDA for

870	elderly populations. Firstly, whilst it is widely held that haematological abnormalities represent the

871	first symptom of CD, it has long been understood that neurological deficits often present

872	first(291,303). Moreover, experimental investigations from the 1980s and 90s suggest that the absence

873	of macrocytic anaemia is commonplace, relating to ~1/3 of cases, whilst the absence of neurological

874	symptoms appears to be much less common(264,271,272). Interestingly, severe incidence for one set of

875	symptoms (e.g. neurological symptoms) has been associated with absence of the other (e.g.

876	haematological symptoms)(264,267), and this inverse relationship is reflected in measures of B12

877	status(270,271,304) and B12 analogues(304). This suggests that B12 utilization in the deficient state is

878	subject to antagonistic or compensatory mechanisms which are determined at the level of the

879	individual. The relative proportion of people affected by each or both sets of symptoms is unclear

880	from the literature, since there is a shortfall of relevant and epidemiologically representative data.

881	With regard to the timeline of symptom development, it is again interesting to note that the great

882	majority of those with only neurological symptoms (~80%) do not present until sometime between






885	Emerging perspectives on sarcopenia in which declines in muscle mass and function in older age

886	are seen as neuromuscular rather than simply muscular, have raised important questions in terms of

887	research into potential therapies. Nutritional intervention strategies for sarcopenia have a strong

888	theoretical basis and much work in terms of protein and individual amino acids is evident in the

889	literature, with varying success reported. Elderly subjects frequently present with multiple,

890	potentially-confounding factors in terms of research, many of which may be nutritional in nature. In

891	this connection the present discussion has examined the potential role of selected B-vitamins in

892	normal and pathophysiological modes of neuromuscular function. Several key themes emerge,

893	notably those surrounding the adequacy of the knowledge base in terms of older adults’

894	requirements for B-vitamins and the clear similarities between certain deficiency and disease/frailty

895	states associated with older age. It is possible therefore that compromised intake or function of the

896	B-vitamins discussed may induce, mimic or aggravate key aspects of neuromuscular compromise as

897	observed in age-related sarcopenia.

898	The available evidence regarding the B-vitamins considered and their potential role in the

899	development of sarcopenia presents an interesting mix of clinical observations and biophysiologic

900	mechanisms. TD, for example, has long been characterized by reduced appetite, weight loss and

901	neural and neuromuscular compromise mirroring aetiological features of age-related sarcopenia













903	with anorexia and with reductions in hydrochloric acid in gastric secretions, leading to specific and

904	general nutrient deficiencies. Furthermore, low niacin intake can lead to motorneuron

905	chromatolysis. With respect to B6 deficiency, axonal degeneration and pathologic disturbances in

906	Schwann cells has been described as affecting distal motorneurons and is associated with loss of

907	motor function. In folate deficiency, in addition to the correlation between hyperhomocysteinaemia

908	and decline in neuromuscular function, it is possible that the induction of mass misincorporation of

909	uracil into DNA as a result of low folate status and subsequent chromosomal instability could

910	inhibit muscle synthetic and repair processes. Similarly, compromised B12 status is a known risk for

911	muscle weakness, abnormal reflexes, spasticity, gait ataxia and myelopathies, likely due to





914	It is concluded therefore that for any meaningful investigation of the development or treatment of

915	sarcopenia, it is important to consider, and where possible eliminate, deficiencies of B-vitamins the

916	lack of which may impinge on muscle, nerve or the neuromuscular nexus. While it is not possible to

917	conclude that one or more B-vitamin deficiencies are causative of sarcopenia, within the mélange of

918	known and surmised risk factors, such deficiencies warrant serious consideration. This seems

919	especially true given the ease and relatively low cost of addressing such nutritional inadequacy. The

920	evidence base for recommended daily quantities of micronutrients could usefully be contemporized

921	in terms of adequacy for an ageing demographic, especially where there is a paucity of (functional)

922	metabolic data available. Finally, given the increasing number of individuals reaching their ninth
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